Memorial Sloan-Kettering, Cornell and Hybrid Silica Technologies have used a silica nanoparticle–based imaging agent to detect micrometastases in lymph nodes of two animal models of melanoma. The investigators have begun a Phase 0 trial in metastatic melanoma patients and are forming a new company, Clinical Silica Technologies, to pursue diagnostic and therapeutic applications of the technology.